Skip to main content

Table 2 Risk of tuberculosis in patients with rheumatoid arthritis treated with biologic therapy

From: Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013–2018

  

Anti-TNF

 

All

(n = 4736)

ETA

(n = 934)

INF

(n = 561)

ADA

(n = 1,218)

GOL

(n = 858)

TOC

(n = 1165)

Duration of follow-up (days), median (IQR)

569 (230–1075)

640

(256–1225)

642

(222–1174)

510

(216–931)

475

(204–984)

612

(281–1061)

Person-years

8650.8

1879.7

1087.1

2050.9

1447.5

2185.6

Case of TB, n

48

7

13

12

6

10

Rate/100,000 person-years (95% CI)

554.9

(412.3–727.0)

372.4

(160.0–720.1)

1195.8

(657.8–1968.5)

585.1

(313.3–981.2)

414.5

(164.7–839.9)

457.5

(229.3–802.4)

Adjusted IRRa

 

1.00 (ref)

3.06

(1.22–7.69)

1.69

(0.66–4.33)

1.22

(0.41–3.67)

1.25

(0.47–3.31)

  1. TNF tumor necrosis factor, ETA etanercept, INF infliximab, ADA adalimumab, GOL golimumab, TOC tocilizumab, IQR interquartile range, TB tuberculosis, CI confidence interval, IRR incidence rate ratio
  2. aThe IRR was adjusted for age, sex, and entry year